Singapore-based biotechnology firm Tikva Allocell has successfully closed an $8 million Series A financing round led by Kantharos Capital. The funding is earmarked to advance the company's lead candidate, TAVST01, an innovative off-the-shelf cell therapy for solid tumors. This strategic investment marks a significant step forward in addressing long-standing challenges in treating cancers that have resisted previous therapeutic approaches.
Advancing a Novel Solid Tumor Therapy
The proceeds from this financing will be instrumental in completing the necessary Investigational New Drug (IND) enabling activities for TAVST01. Tikva Allocell aims to submit its IND application to regulators by the end of 2026. Following regulatory clearance, the company plans to launch a Phase 1 clinical trial for patients with advanced cancers at sites in Singapore and the United States.
TAVST01 is designed to target B7-H3, a protein commonly found on the surface of a wide array of difficult-to-treat solid tumors. This includes prevalent cancers such as lung, breast, prostate, and pancreatic cancers, as well as certain pediatric malignancies. By targeting B7-H3, the therapy holds the potential to offer a new treatment avenue for a broad patient population with significant unmet medical needs.
Overcoming Allogeneic Cell Therapy Hurdles
A primary obstacle for conventional donor-derived cell therapies has been their rapid elimination by the patient's own immune system. Tikva's approach circumvents this issue by using T cells specific to the Epstein-Barr virus (EBV), which the body naturally maintains for years. This foundation provides the engineered cells with the durability and persistence required to effectively combat solid tumors.
The company's technology is built upon its ALLO SerpinB9 EBVST platform, licensed from Baylor College of Medicine. These therapeutic cells are engineered with a receptor to find B7-H3 and an optimized form of SerpinB9 protein. This unique SerpinB9 "armor" shields the cells from immune rejection, allowing them to remain active and attack the tumor.
Dr. Ivan Horak, CEO of Tikva Allocell, explained that their technology addresses the core persistence issue that has limited cell therapy in solid tumors. He noted that the approach uses a naturally sustained T cell engineered to withstand rejection with minimal gene editing. This financing positions the company to advance TAVST01 toward clinical evaluation for patients who need new options.
Investor Confidence and Scientific Foundation
Terence Tan, Managing Partner at Kantharos Capital, expressed strong confidence in Tikva's scientific platform and its experienced leadership team. He stated that the company is tackling fundamental challenges that have previously constrained allogeneic cell therapies. Kantharos Capital looks forward to supporting Tikva as it moves toward its IND submission and subsequent clinical trials.
Tikva's scientific foundation is rooted in decades of pioneering research from Baylor College of Medicine. The core technology was developed by leaders in virus-specific T-cell biology, including Dr. Malcolm Brenner, Dr. Cliona Rooney, and Dr. Helen Heslop. These co-founders continue to serve as scientific advisors, providing deep expertise as the company advances its pipeline.
The successful $8 million funding round represents a pivotal moment for Tikva Allocell and its mission to treat solid tumors. With a novel platform designed for persistence and efficacy, the company is well-positioned to progress its lead candidate, TAVST01, into the clinic. This development offers renewed hope for patients with advanced cancers and could significantly expand the reach of cell therapy.